ID

17381

Description

CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL); ODM derived from: https://clinicaltrials.gov/show/NCT01653717

Link

https://clinicaltrials.gov/show/NCT01653717

Keywords

  1. 9/10/16 9/10/16 -
Uploaded on

September 10, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Advanced Cancers NCT01653717

Eligibility Advanced Cancers NCT01653717

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients with a history of b-cll, who have received at least 2 lines of standard chemoimmunotherapy and have persistent disease.
Description

b-cll

Data type

boolean

Alias
UMLS CUI [1]
C0023434
confirmed history of cd19 positivity by flow cytometry.
Description

cd19+

Data type

boolean

Alias
UMLS CUI [1]
C1267885
at least 8 weeks from last cytotoxic chemotherapy. patients may continue ibrutinib or lenalidomide. these drugs will be discontinued 1 week prior to start of lymphodepleting chemotherapy.
Description

cytotoxic chemotherapy

Data type

boolean

Alias
UMLS CUI [1]
C0677881
karnofsky performance scale > 60%.
Description

karnofsky

Data type

boolean

Alias
UMLS CUI [1]
C0206065
absolute lymphocyte count >100/ul.
Description

absolute lymphocyte count

Data type

boolean

Alias
UMLS CUI [1]
C3544087
adequate hepatic function, as defined by sgpt <3 x upper limit of normal; serum bilirubin and alkaline phosphatase <2 x upper limit of normal, or considered not clinically significant by the study doctor or designee.
Description

hepatic function

Data type

boolean

Alias
UMLS CUI [1]
C0232741
able to provide written informed consent.
Description

informed consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
18-80 years of age.
Description

age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
patient or patient's legal representative, parent(s) or guardian able to provide written informed consent for the long-term follow-up gene therapy study.
Description

written informed consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
positive beta hcg in female of child-bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization or lactating females.
Description

beta hcg positive

Data type

boolean

Alias
UMLS CUI [1]
C0813152
patients with known allergy to bovine or murine products.
Description

hypersensivity

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0007452
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0591833
positive serology for hiv.
Description

hiv+

Data type

boolean

Alias
UMLS CUI [1]
C0019699
presence of autoimmune phenomenon (aiha, itp) requiring steroid therapy.
Description

steroid therapy

Data type

boolean

Alias
UMLS CUI [1]
C0149783
presence of grade 3 or greater toxicity from the previous treatment.
Description

toxicity

Data type

boolean

Alias
UMLS CUI [1]
C0013221
concomitant use of other investigational agents (ibrutinib or lenalidomide are allowed).
Description

investigational agents

Data type

boolean

Alias
UMLS CUI [1]
C1875319

Similar models

Eligibility Advanced Cancers NCT01653717

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
b-cll
Item
patients with a history of b-cll, who have received at least 2 lines of standard chemoimmunotherapy and have persistent disease.
boolean
C0023434 (UMLS CUI [1])
cd19+
Item
confirmed history of cd19 positivity by flow cytometry.
boolean
C1267885 (UMLS CUI [1])
cytotoxic chemotherapy
Item
at least 8 weeks from last cytotoxic chemotherapy. patients may continue ibrutinib or lenalidomide. these drugs will be discontinued 1 week prior to start of lymphodepleting chemotherapy.
boolean
C0677881 (UMLS CUI [1])
karnofsky
Item
karnofsky performance scale > 60%.
boolean
C0206065 (UMLS CUI [1])
absolute lymphocyte count
Item
absolute lymphocyte count >100/ul.
boolean
C3544087 (UMLS CUI [1])
hepatic function
Item
adequate hepatic function, as defined by sgpt <3 x upper limit of normal; serum bilirubin and alkaline phosphatase <2 x upper limit of normal, or considered not clinically significant by the study doctor or designee.
boolean
C0232741 (UMLS CUI [1])
informed consent
Item
able to provide written informed consent.
boolean
C0021430 (UMLS CUI [1])
age
Item
18-80 years of age.
boolean
C0001779 (UMLS CUI [1])
written informed consent
Item
patient or patient's legal representative, parent(s) or guardian able to provide written informed consent for the long-term follow-up gene therapy study.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
beta hcg positive
Item
positive beta hcg in female of child-bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization or lactating females.
boolean
C0813152 (UMLS CUI [1])
hypersensivity
Item
patients with known allergy to bovine or murine products.
boolean
C0020517 (UMLS CUI [1,1])
C0007452 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0591833 (UMLS CUI [2,2])
hiv+
Item
positive serology for hiv.
boolean
C0019699 (UMLS CUI [1])
steroid therapy
Item
presence of autoimmune phenomenon (aiha, itp) requiring steroid therapy.
boolean
C0149783 (UMLS CUI [1])
toxicity
Item
presence of grade 3 or greater toxicity from the previous treatment.
boolean
C0013221 (UMLS CUI [1])
investigational agents
Item
concomitant use of other investigational agents (ibrutinib or lenalidomide are allowed).
boolean
C1875319 (UMLS CUI [1])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial